Large-scale production of human pluripotent stem cell derived cardiomyocytes

Advanced Drug Delivery Reviews

Volumn 96, Issue , 2016, Pages 18-30

  Kempf, Henning ^a   Andree, Birgit ^a   Zweigerdt, Robert ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Bioreactor; Cardiomyocytes; Differentiation; Human pluripotent stem cells; Process development; Scale up

Indexed keywords

BIOREACTORS; CELLS; CYTOLOGY; DIFFERENTIATION (CALCULUS); PLANTS (BOTANY); TISSUE ENGINEERING;

CARDIOMYOCYTES; CLINICAL TRANSLATION; LARGE SCALE PRODUCTIONS; PLURIPOTENT STEM CELLS; PROCESS DEVELOPMENT; REGENERATIVE MEDICINE; SCALE-UP; THREEDIMENSIONAL (3-D);

STEM CELLS;

CELL SURFACE MARKER;

ARRHYTHMOGENESIS; BIOPROCESS; CARDIAC STEM CELL; CELL AGGREGATION; CELL DIFFERENTIATION; CELL MATURATION; EMBRYONIC STEM CELL; ENDOTHELIUM CELL; HEART INFARCTION; HEART MUSCLE CELL; HUMAN; MICROCARRIER CULTURE; MONOLAYER CULTURE; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; STEM CELL CULTURE; STEM CELL EXPANSION; STEM CELL TRANSPLANTATION; STIRRED REACTOR; SUSPENSION CELL CULTURE; ANIMAL; CARDIAC MUSCLE CELL; CELL CULTURE TECHNIQUE; CYTOLOGY; DEVICES; METABOLISM; PROCEDURES; STEM CELL RESEARCH; TISSUE ENGINEERING; TRANSPLANTATION; WNT SIGNALING PATHWAY;

ANIMALS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; HUMANS; MYOCYTES, CARDIAC; PLURIPOTENT STEM CELLS; STEM CELL RESEARCH; TISSUE ENGINEERING; WNT SIGNALING PATHWAY;

EID: 84951863050     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.11.016     Document Type: Review

References (158)

1. Zweigerdt R. The art of cobbling a running pump-will human embryonic stem cells mend broken hearts?. Semin. Cell Dev. Biol. 2007, 18:794-804.
2. Soonpaa M.H., Rubart M., Field L.J. Challenges measuring cardiomyocyte renewal. Biochim. Biophys. Acta 2013, 1833:799-803.
3. Bergmann O., Bhardwaj R.D., Bernard S., Zdunek S., Barnabe-Heider F., Walsh S., Zupicich J., Alkass K., Buchholz B.A., Druid H., Jovinge S., Frisen J. Evidence for cardiomyocyte renewal in humans. Science 2009, 324:98-102.
4. van Berlo J.H., Kanisicak O., Maillet M., Vagnozzi R.J., Karch J., Lin S.C., Middleton R.C., Marban E., Molkentin J.D. c-kit+cells minimally contribute cardiomyocytes to the heart. Nature 2014, 509:337-341.
5. Rojas S.V., Avsar M., Uribarri A., Hanke J.S., Haverich A., Schmitto J.D. A new era of ventricular assist device surgery: less invasive procedures. Minerva Chir. 2015, 70:63-68.
6. Murry C.E., Field L.J., Menasche P. Cell-based cardiac repair: reflections at the 10-year point. Circulation 2005, 112:3174-3183.
7. Donndorf P., Strauer B.E., Haverich A., Steinhoff G. Stem cell therapy for the treatment of acute myocardial infarction and chronic ischemic heart disease. Curr. Pharm. Biotechnol. 2013, 14:12-19.
8. Parsa H., Ronaldson K., Vunjak-Novakovic G. Bioengineering methods for myocardial regeneration. Adv. Drug Deliv. Rev 2016, 96:195-202.
9. Masuda S., Shimizu T. Three-dimensional cardiac tissue fabrication based on cell sheet technology. Adv. Drug Deliv. Rev 2016, 96:103-109.
10. Tzatzalos E., Abilez O.J., Shukla P., Wu J.C. Engineered heart tissues and induced pluripotent stem cells: macro- and microstructures for disease modeling, drug screening, and translational studies. Adv. Drug Deliv. Rev 2016, 96:234-244.
11. Liaw N.Y., Zimmermann W.-H. Mechanical stimulation in the engineering of heart muscle. Adv. Drug Deliv. Rev 2016, 96:156-160.
12. Templin C., Zweigerdt R., Schwanke K., Olmer R., Ghadri J.R., Emmert M.Y., Muller E., Kuest S.M., Cohrs S., Schibli R., Kronen P., Hilbe M., Reinisch A., Strunk D., Haverich A., Hoerstrup S., Luscher T.F., Kaufmann P.A., Landmesser U., Martin U. Transplantation and tracking of human-induced pluripotent stem cells in a pig model of myocardial infarction: assessment of cell survival, engraftment, and distribution by hybrid single photon emission computed tomography/computed tomography of sodium iodide symporter transgene expression. Circulation 2012, 126:430-439.
13. Ye L., Chang Y.H., Xiong Q., Zhang P., Zhang L., Somasundaram P., Lepley M., Swingen C., Su L., Wendel J.S., Guo J., Jang A., Rosenbush D., Greder L., Dutton J.R., Zhang J., Kamp T.J., Kaufman D.S., Ge Y., Zhang J. Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cell-derived cardiovascular cells. Cell Stem Cell 2014, 15:750-761.
14. Orlova V.V., van den Hil F.E., Petrus-Reurer S., Drabsch Y., Ten Dijke P., Mummery C.L. Generation, expansion and functional analysis of endothelial cells and pericytes derived from human pluripotent stem cells. Nat. Protoc. 2014, 9:1514-1531.
15. Lian X., Bao X., Al-Ahmad A., Liu J., Wu Y., Dong W., Dunn K.K., Shusta E.V., Palecek S.P. Efficient differentiation of human pluripotent stem cells to endothelial progenitors via small-molecule activation of WNT signaling. Stem Cell Rep. 2014, 3:804-816.
16. Dar A., Domev H., Ben-Yosef O., Tzukerman M., Zeevi-Levin N., Novak A., Germanguz I., Amit M., Itskovitz-Eldor J. Multipotent vasculogenic pericytes from human pluripotent stem cells promote recovery of murine ischemic limb. Circulation 2012, 125:87-99.
17. Patsch C., Challet-Meylan L., Thoma E.C., Urich E., Heckel T., O'Sullivan J.F., Grainger S.J., Kapp F.G., Sun L., Christensen K., Xia Y., Florido M.H., He W., Pan W., Prummer M., Warren C.R., Jakob-Roetne R., Certa U., Jagasia R., Freskgard P.O., Adatto I., Kling D., Huang P., Zon L.I., Chaikof E.L., Gerszten R.E., Graf M., Iacone R., Cowan C.A. Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells. Nat. Cell Biol. 2015, 17:994-1003.
18. Chen T.S., Arslan F., Yin Y., Tan S.S., Lai R.C., Choo A.B., Padmanabhan J., Lee C.N., de Kleijn D.P., Lim S.K. Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs. J. Transl. Med. 2011, 9:47.
19. Kempf H., Olmer R., Kropp C., Ruckert M., Jara-Avaca M., Robles-Diaz D., Franke A., Elliott D.A., Wojciechowski D., Fischer M., Roa Lara A., Kensah G., Gruh I., Haverich A., Martin U., Zweigerdt R. Controlling expansion and cardiomyogenic differentiation of human pluripotent stem cells in scalable suspension culture. Stem Cell Rep. 2014, 3:1132-1146.
20. Zweigerdt R. Large scale production of stem cells and their derivatives. Adv. Biochem. Eng. Biotechnol. 2009, 114:201-235.
21. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
22. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
23. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., Nie J., Jonsdottir G.A., Ruotti V., Stewart R., Slukvin I.I., Thomson J.A. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
24. Eder A., Vollert I., Hansen A., Eschenhagen T. Human engineered heart tissue as a model system for drug testing. Adv. Drug Deliv. Rev 2016, 96:214-224.
25. Tanaka A., Yuasa S., Node K., Fukuda K. Cardiovascular disease modeling using patient-specific induced pluripotent stem cells. Int. J. Mol. Sci. 2015, 16:18894-18922.
26. Fatima A., Kaifeng S., Dittmann S., Xu G., Gupta M.K., Linke M., Zechner U., Nguemo F., Milting H., Farr M., Hescheler J., Saric T. The disease-specific phenotype in cardiomyocytes derived from induced pluripotent stem cells of two long QT syndrome type 3 patients. PLoS One 2013, 8:e83005.
27. Schwartz S.D., Hubschman J.P., Heilwell G., Franco-Cardenas V., Pan C.K., Ostrick R.M., Mickunas E., Gay R., Klimanskaya I., Lanza R. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 2012, 379:713-720.
28. Cyranoski D. Japanese woman is first recipient of next-generation stem cells 2014, Nature Publishing Group.
29. ViaCyte A safety, tolerability, and efficacy study of VC-01™ combination product in subjects with type I diabetes mellitus http://clinicaltrials.gov.
30. Menasche P., Vanneaux V., Fabreguettes J.R., Bel A., Tosca L., Garcia S., Bellamy V., Farouz Y., Pouly J., Damour O., Perier M.C., Desnos M., Hagege A., Agbulut O., Bruneval P., Tachdjian G., Trouvin J.H., Larghero J. Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: a translational experience. Eur. Heart J. 2015, 36:743-750.
31. Okita K., Nagata N., Yamanaka S. Immunogenicity of induced pluripotent stem cells. Circ. Res. 2011, 109:720-721.
32. Zhao T., Zhang Z.N., Rong Z., Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011, 474:212-215.
33. Araki R., Uda M., Hoki Y., Sunayama M., Nakamura M., Ando S., Sugiura M., Ideno H., Shimada A., Nifuji A., Abe M. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 2013, 494:100-104.
34. de Almeida P.E., Meyer E.H., Kooreman N.G., Diecke S., Dey D., Sanchez-Freire V., Hu S., Ebert A., Odegaard J., Mordwinkin N.M., Brouwer T.P., Lo D., Montoro D.T., Longaker M.T., Negrin R.S., Wu J.C. Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance. Nat. Commun. 2014, 5:3903.
35. Zhao T., Zhang Z.N., Westenskow P.D., Todorova D., Hu Z., Lin T., Rong Z., Kim J., He J., Wang M., Clegg D.O., Yang Y.G., Zhang K., Friedlander M., Xu Y. Humanized mice reveal differential immunogenicity of cells derived from autologous induced pluripotent stem cells. Cell Stem Cell 2015, 17:353-359.
36. Reardon S., Cyranoski D. Japan stem-cell trial stirs envy. Nature 2014, 513:287-288.
37. Jenkins M.J., Farid S.S. Human pluripotent stem cell-derived products: advances towards robust, scalable and cost-effective manufacturing strategies. Biotechnol. J. 2015, 10:83-95.
38. Zimmermann A., Preynat-Seauve O., Tiercy J.M., Krause K.H., Villard J. Haplotype-based banking of human pluripotent stem cells for transplantation: potential and limitations. Stem Cells Dev. 2012, 21:2364-2373.
39. Hoppe N., Miola J. Medical Law and Medical Ethics 2014, Cambridge University Press.
40. Haase A., Olmer R., Schwanke K., Wunderlich S., Merkert S., Hess C., Zweigerdt R., Gruh I., Meyer J., Wagner S., Maier L.S., Han D.W., Glage S., Miller K., Fischer P., Scholer H.R., Martin U. Generation of induced pluripotent stem cells from human cord blood. Cell Stem Cell 2009, 5:434-441.
41. Chen V.C., Ye J., Shukla P., Hua G., Chen D., Lin Z., Liu J.C., Chai J., Gold J., Wu J., Hsu D., Couture L.A. Development of a scalable suspension culture for cardiac differentiation from human pluripotent stem cells. Stem Cell Res. 2015, 15:365-375.
42. Chu L., Robinson D.K. Industrial choices for protein production by large-scale cell culture. Curr. Opin. Biotechnol. 2001, 12:180-187.
43. Mummery C.L., Zhang J., Ng E.S., Elliott D.A., Elefanty A.G., Kamp T.J. Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circ. Res. 2012, 111:344-358.
44. Amit M., Chebath J., Margulets V., Laevsky I., Miropolsky Y., Shariki K., Peri M., Blais I., Slutsky G., Revel M., Itskovitz-Eldor J. Suspension culture of undifferentiated human embryonic and induced pluripotent stem cells. Stem Cell Rev. 2010, 6:248-259.
45. Watanabe K., Ueno M., Kamiya D., Nishiyama A., Matsumura M., Wataya T., Takahashi J.B., Nishikawa S., Nishikawa S., Muguruma K., Sasai Y. A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat. Biotechnol. 2007, 25:681-686.
46. Bandaranayake A.D., Almo S.C. Recent advances in mammalian protein production. FEBS Lett. 2014, 588:253-260.
47. Konze S.A., van Diepen L., Schroder A., Olmer R., Moller H., Pich A., Weissmann R., Kuss A.W., Zweigerdt R., Buettner F.F. Cleavage of E-cadherin and beta-catenin by calpain affects Wnt signaling and spheroid formation in suspension cultures of human pluripotent stem cells. Mol. Cell. Proteomics 2014, 13:990-1007.
48. Lei Y., Schaffer D.V. A fully defined and scalable 3D culture system for human pluripotent stem cell expansion and differentiation. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E5039-E5048.
49. Lou Y.R., Kanninen L., Kuisma T., Niklander J., Noon L.A., Burks D., Urtti A., Yliperttula M. The use of nanofibrillar cellulose hydrogel as a flexible three-dimensional model to culture human pluripotent stem cells. Stem Cells Dev. 2014, 23:380-392.
50. Celiz A.D., Smith J.G., Langer R., Anderson D.G., Winkler D.A., Barrett D.A., Davies M.C., Young L.E., Denning C., Alexander M.R. Materials for stem cell factories of the future. Nat. Mater. 2014, 13:570-579.
51. Zweigerdt R., Burg M., Willbold E., Abts H., Ruediger M. Generation of confluent cardiomyocyte monolayers derived from embryonic stem cells in suspension: a cell source for new therapies and screening strategies. Cytotherapy 2003, 5:399-413.
52. Zweigerdt R., Olmer R., Singh H., Haverich A., Martin U. Scalable expansion of human pluripotent stem cells in suspension culture. Nat. Protoc. 2011, 6:689-700.
53. Otsuji T.G., Bin J., Yoshimura A., Tomura M., Tateyama D., Minami I., Yoshikawa Y., Aiba K., Heuser J.E., Nishino T., Hasegawa K., Nakatsuji N. A 3D sphere culture system containing functional polymers for large-scale human pluripotent stem cell production. Stem Cell Rep. 2014, 2:734-745.
54. Chen K.G., Mallon B.S., McKay R.D., Robey P.G. Human pluripotent stem cell culture: considerations for maintenance, expansion, and therapeutics. Cell Stem Cell 2014, 14:13-26.
55. Olmer R., Lange A., Selzer S., Kasper C., Haverich A., Martin U., Zweigerdt R. Suspension culture of human pluripotent stem cells in controlled, stirred bioreactors. Tissue Eng. Part C Methods 2012, 18:772-784.
56. dos Santos F.F., Andrade P.Z., da Silva C.L., Cabral J.M. Bioreactor design for clinical-grade expansion of stem cells. Biotechnol. J. 2013, 8:644-654.
57. Ilin Y., Kraft M.L. Secondary ion mass spectrometry and Raman spectroscopy for tissue engineering applications. Curr. Opin. Biotechnol. 2015, 31:108-116.
58. Lorbeer R.A., Heidrich M., Lorbeer C., Ramirez Ojeda D.F., Bicker G., Meyer H., Heisterkamp A. Highly efficient 3D fluorescence microscopy with a scanning laser optical tomograph. Opt. Express 2011, 19:5419-5430.
59. Fong W.J., Tan H.L., Choo A., Oh S.K. Perfusion cultures of human embryonic stem cells. Bioprocess Biosyst. Eng. 2005, 27:381-387.
60. Serra M., Brito C., Sousa M.F., Jensen J., Tostoes R., Clemente J., Strehl R., Hyllner J., Carrondo M.J., Alves P.M. Improving expansion of pluripotent human embryonic stem cells in perfused bioreactors through oxygen control. J. Biotechnol. 2010, 148:208-215.
61. Phillips B.W., Lim R.Y., Tan T.T., Rust W.L., Crook J.M. Efficient expansion of clinical-grade human fibroblasts on microcarriers: cells suitable for ex vivo expansion of clinical-grade hESCs. J. Biotechnol. 2008, 134:79-87.
62. Oh S.K., Chen A.K., Mok Y., Chen X., Lim U.M., Chin A., Choo A.B., Reuveny S. Long-term microcarrier suspension cultures of human embryonic stem cells. Stem Cell Res. 2009, 2:219-230.
63. Kleger A., Seufferlein T., Malan D., Tischendorf M., Storch A., Wolheim A., Latz S., Protze S., Porzner M., Proepper C., Brunner C., Katz S.F., Varma Pusapati G., Bullinger L., Franz W.M., Koehntop R., Giehl K., Spyrantis A., Wittekindt O., Lin Q., Zenke M., Fleischmann B.K., Wartenberg M., Wobus A.M., Boeckers T.M., Liebau S. Modulation of calcium-activated potassium channels induces cardiogenesis of pluripotent stem cells and enrichment of pacemaker-like cells. Circulation 2010, 122:1823-1836.
64. Lam A.T., Chen A.K., Ting S.Q., Reuveny S., Oh S.K. Integrated processes for expansion and differentiation of human pluripotent stem cells in suspended microcarriers cultures. Biochem. Biophys. Res. Commun. 2015, (Epub ahead of print). 10.1016/j.bbrc.2015.09.079.
65. Silva M.M., Rodrigues A.F., Correia C., Sousa M.F., Brito C., Coroadinha A.S., Serra M., Alves P.M. Robust expansion of human pluripotent stem cells: integration of bioprocess design with transcriptomic and metabolomic characterization. Stem Cells Transl. Med. 2015, 4:731-742.
66. Polykandriotis E., Arkudas A., Horch R.E., Kneser U. To matrigel or not to matrigel. Am. J. Pathol. 2008, 172:1441. (author reply 1441-1442).
67. Ellerstrom C., Strehl R., Noaksson K., Hyllner J., Semb H. Facilitated expansion of human embryonic stem cells by single-cell enzymatic dissociation. Stem Cells 2007, 25:1690-1696.
68. Amit M., Laevsky I., Miropolsky Y., Shariki K., Peri M., Itskovitz-Eldor J. Dynamic suspension culture for scalable expansion of undifferentiated human pluripotent stem cells. Nat. Protoc. 2011, 6:572-579.
69. Olmer R., Haase A., Merkert S., Cui W., Palecek J., Ran C., Kirschning A., Scheper T., Glage S., Miller K., Curnow E.C., Hayes E.S., Martin U. Long term expansion of undifferentiated human iPS and ES cells in suspension culture using a defined medium. Stem Cell Res. 2010, 5:51-64.
70. Singh H., Mok P., Balakrishnan T., Rahmat S.N., Zweigerdt R. Up-scaling single cell-inoculated suspension culture of human embryonic stem cells. Stem Cell Res. 2010, 4:165-179.
71. Wang L., Schulz T.C., Sherrer E.S., Dauphin D.S., Shin S., Nelson A.M., Ware C.B., Zhan M., Song C.Z., Chen X., Brimble S.N., McLean A., Galeano M.J., Uhl E.W., D'Amour K.A., Chesnut J.D., Rao M.S., Blau C.A., Robins A.J. Self-renewal of human embryonic stem cells requires insulin-like growth factor-1 receptor and ERBB2 receptor signaling. Blood 2007, 110:4111-4119.
72. Chen V.C., Couture S.M., Ye J., Lin Z., Hua G., Huang H.I., Wu J., Hsu D., Carpenter M.K., Couture L.A. Scalable GMP compliant suspension culture system for human ES cells. Stem Cell Res. 2012, 8:388-402.
73. Wang Y., Chou B.K., Dowey S., He C., Gerecht S., Cheng L. Scalable expansion of human induced pluripotent stem cells in the defined xeno-free E8 medium under adherent and suspension culture conditions. Stem Cell Res. 2013, 11:1103-1116.
74. Hunt M.M., Meng G., Rancourt D.E., Gates I.D., Kallos M.S. Factorial experimental design for the culture of human embryonic stem cells as aggregates in stirred suspension bioreactors reveals the potential for interaction effects between bioprocess parameters. Tissue Eng. Part C Methods 2014, 20:76-89.
75. Abbasalizadeh S., Larijani M.R., Samadian A., Baharvand H. Bioprocess development for mass production of size-controlled human pluripotent stem cell aggregates in stirred suspension bioreactor. Tissue Eng. Part C Methods 2012, 18:831-851.
76. Kehat I., Kenyagin-Karsenti D., Snir M., Segev H., Amit M., Gepstein A., Livne E., Binah O., Itskovitz-Eldor J., Gepstein L. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J. Clin. Invest. 2001, 108:407-414.
77. Mummery C., Ward-van Oostwaard D., Doevendans P., Spijker R., van den Brink S., Hassink R., van der Heyden M., Opthof T., Pera M., de la Riviere A.B., Passier R., Tertoolen L. Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation 2003, 107:2733-2740.
78. Burridge P.W., Keller G., Gold J.D., Wu J.C. Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell 2012, 10:16-28.
79. Yang L., Soonpaa M.H., Adler E.D., Roepke T.K., Kattman S.J., Kennedy M., Henckaerts E., Bonham K., Abbott G.W., Linden R.M., Field L.J., Keller G.M. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature 2008, 453:524-528.
80. Laflamme M.A., Chen K.Y., Naumova A.V., Muskheli V., Fugate J.A., Dupras S.K., Reinecke H., Xu C., Hassanipour M., Police S., O'Sullivan C., Collins L., Chen Y., Minami E., Gill E.A., Ueno S., Yuan C., Gold J., Murry C.E. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat. Biotechnol. 2007, 25:1015-1024.
81. Burridge P.W., Thompson S., Millrod M.A., Weinberg S., Yuan X., Peters A., Mahairaki V., Koliatsos V.E., Tung L., Zambidis E.T. A universal system for highly efficient cardiac differentiation of human induced pluripotent stem cells that eliminates interline variability. PLoS One 2011, 6:e18293.
82. Kattman S.J., Witty A.D., Gagliardi M., Dubois N.C., Niapour M., Hotta A., Ellis J., Keller G. Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell 2011, 8:228-240.
83. Elliott D.A., Braam S.R., Koutsis K., Ng E.S., Jenny R., Lagerqvist E.L., Biben C., Hatzistavrou T., Hirst C.E., Yu Q.C., Skelton R.J., Ward-van Oostwaard D., Lim S.M., Khammy O., Li X., Hawes S.M., Davis R.P., Goulburn A.L., Passier R., Prall O.W., Haynes J.M., Pouton C.W., Kaye D.M., Mummery C.L., Elefanty A.G., Stanley E.G. NKX2-5(eGFP/w) hESCs for isolation of human cardiac progenitors and cardiomyocytes. Nat. Methods 2011, 8:1037-1040.
84. Kawamura M., Miyagawa S., Miki K., Saito A., Fukushima S., Higuchi T., Kawamura T., Kuratani T., Daimon T., Shimizu T., Okano T., Sawa Y. Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation 2012, 126:S29-S37.
85. Freund C., Ward-van Oostwaard D., Monshouwer-Kloots J., van den Brink S., van Rooijen M., Xu X., Zweigerdt R., Mummery C., Passier R. Insulin redirects differentiation from cardiogenic mesoderm and endoderm to neuroectoderm in differentiating human embryonic stem cells. Stem Cells 2008, 26:724-733.
86. Xu X.Q., Graichen R., Soo S.Y., Balakrishnan T., Rahmat S.N., Sieh S., Tham S.C., Freund C., Moore J., Mummery C., Colman A., Zweigerdt R., Davidson B.P. Chemically defined medium supporting cardiomyocyte differentiation of human embryonic stem cells. Differentiation 2008, 76:958-970.
87. Passier R., Oostwaard D.W., Snapper J., Kloots J., Hassink R.J., Kuijk E., Roelen B., de la Riviere A.B., Mummery C. Increased cardiomyocyte differentiation from human embryonic stem cells in serum-free cultures. Stem Cells 2005, 23:772-780.
88. Graichen R., Xu X., Braam S.R., Balakrishnan T., Norfiza S., Sieh S., Soo S.Y., Tham S.C., Mummery C., Colman A., Zweigerdt R., Davidson B.P. Enhanced cardiomyogenesis of human embryonic stem cells by a small molecular inhibitor of p38 MAPK. Differentiation 2008, 76:357-370.
89. Gaur M., Ritner C., Sievers R., Pedersen A., Prasad M., Bernstein H.S., Yeghiazarians Y. Timed inhibition of p38MAPK directs accelerated differentiation of human embryonic stem cells into cardiomyocytes. Cytotherapy 2010, 12:807-817.
90. Kempf H., Lecina M., Ting S., Zweigerdt R., Oh S. Distinct regulation of mitogen-activated protein kinase activities is coupled with enhanced cardiac differentiation of human embryonic stem cells. Stem Cell Res. 2011, 7:198-209.
91. Ueno S., Weidinger G., Osugi T., Kohn A.D., Golob J.L., Pabon L., Reinecke H., Moon R.T., Murry C.E. Biphasic role for Wnt/beta-catenin signaling in cardiac specification in zebrafish and embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:9685-9690.
92. Ren Y., Lee M.Y., Schliffke S., Paavola J., Amos P.J., Ge X., Ye M., Zhu S., Senyei G., Lum L., Ehrlich B.E., Qyang Y. Small molecule Wnt inhibitors enhance the efficiency of BMP-4-directed cardiac differentiation of human pluripotent stem cells. J. Mol. Cell. Cardiol. 2011, 51:280-287.
93. Willems E., Spiering S., Davidovics H., Lanier M., Xia Z., Dawson M., Cashman J., Mercola M. Small-molecule inhibitors of the Wnt pathway potently promote cardiomyocytes from human embryonic stem cell-derived mesoderm. Circ. Res. 2011, 109:360-364.
94. Hudson J., Titmarsh D., Hidalgo A., Wolvetang E., Cooper-White J. Primitive cardiac cells from human embryonic stem cells. Stem Cells Dev. 2012, 21:1513-1523.
95. Minami I., Yamada K., Otsuji T.G., Yamamoto T., Shen Y., Otsuka S., Kadota S., Morone N., Barve M., Asai Y., Tenkova-Heuser T., Heuser J.E., Uesugi M., Aiba K., Nakatsuji N. A small molecule that promotes cardiac differentiation of human pluripotent stem cells under defined, cytokine- and xeno-free conditions. Cell Rep. 2012, 2:1448-1460.
96. Gonzalez R., Lee J.W., Schultz P.G. Stepwise chemically induced cardiomyocyte specification of human embryonic stem cells. Angew. Chem. 2011, 50:11181-11185.
97. David R., Brenner C., Stieber J., Schwarz F., Brunner S., Vollmer M., Mentele E., Muller-Hocker J., Kitajima S., Lickert H., Rupp R., Franz W.M. MesP1 drives vertebrate cardiovascular differentiation through Dkk-1-mediated blockade of Wnt-signalling. Nat. Cell Biol. 2008, 10:338-345.
98. Lian X., Hsiao C., Wilson G., Zhu K., Hazeltine L.B., Azarin S.M., Raval K.K., Zhang J., Kamp T.J., Palecek S.P. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E1848-E1857.
99. Lian X., Zhang J., Azarin S.M., Zhu K., Hazeltine L.B., Bao X., Hsiao C., Kamp T.J., Palecek S.P. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/beta-catenin signaling under fully defined conditions. Nat. Protoc. 2013, 8:162-175.
100. Burridge P.W., Matsa E., Shukla P., Lin Z.C., Churko J.M., Ebert A.D., Lan F., Diecke S., Huber B., Mordwinkin N.M., Plews J.R., Abilez O.J., Cui B., Gold J.D., Wu J.C. Chemically defined generation of human cardiomyocytes. Nat. Methods 2014, 11:855-860.
101. Thomson J.A., Itskovitz-Eldor J., Shapiro S.S., Waknitz M.A., Swiergiel J.J., Marshall V.S., Jones J.M. Embryonic stem cell lines derived from human blastocysts. Science 1998, 282:1145-1147.
102. Ting S., Liew S.J., Japson F., Shang F., Chong W.K., Reuveny S., Tham J.Y., Li X., Oh S. Time-resolved video analysis and management system for monitoring cardiomyocyte differentiation processes and toxicology assays. Biotechnol. J. 2014, 9:675-683.
103. Rust W., Balakrishnan T., Zweigerdt R. Cardiomyocyte enrichment from human embryonic stem cell cultures by selection of ALCAM surface expression. Regen. Med. 2009, 4:225-237.
104. Van Hoof D., Dormeyer W., Braam S.R., Passier R., Monshouwer-Kloots J., Ward-van Oostwaard D., Heck A.J., Krijgsveld J., Mummery C.L. Identification of cell surface proteins for antibody-based selection of human embryonic stem cell-derived cardiomyocytes. J. Proteome Res. 2010, 9:1610-1618.
105. Dubois N.C., Craft A.M., Sharma P., Elliott D.A., Stanley E.G., Elefanty A.G., Gramolini A., Keller G. SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. Nat. Biotechnol. 2011, 29:1011-1018.
106. Uosaki H., Fukushima H., Takeuchi A., Matsuoka S., Nakatsuji N., Yamanaka S., Yamashita J.K. Efficient and scalable purification of cardiomyocytes from human embryonic and induced pluripotent stem cells by VCAM1 surface expression. PLoS One 2011, 6:e23657.
107. Davis R.P., Ng E.S., Costa M., Mossman A.K., Sourris K., Elefanty A.G., Stanley E.G. Targeting a GFP reporter gene to the MIXL1 locus of human embryonic stem cells identifies human primitive streak-like cells and enables isolation of primitive hematopoietic precursors. Blood 2008, 111:1876-1884.
108. Fujiwara M., Yan P., Otsuji T.G., Narazaki G., Uosaki H., Fukushima H., Kuwahara K., Harada M., Matsuda H., Matsuoka S., Okita K., Takahashi K., Nakagawa M., Ikeda T., Sakata R., Mummery C.L., Nakatsuji N., Yamanaka S., Nakao K., Yamashita J.K. Induction and enhancement of cardiac cell differentiation from mouse and human induced pluripotent stem cells with cyclosporin-A. PLoS One 2011, 6:e16734.
109. Blin G., Nury D., Stefanovic S., Neri T., Guillevic O., Brinon B., Bellamy V., Rucker-Martin C., Barbry P., Bel A., Bruneval P., Cowan C., Pouly J., Mitalipov S., Gouadon E., Binder P., Hagege A., Desnos M., Renaud J.F., Menasche P., Puceat M. A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. J. Clin. Invest. 2010, 120:1125-1139.
110. Leschik J., Stefanovic S., Brinon B., Puceat M. Cardiac commitment of primate embryonic stem cells. Nat. Protoc. 2008, 3:1381-1387.
111. Evseenko D., Zhu Y., Schenke-Layland K., Kuo J., Latour B., Ge S., Scholes J., Dravid G., Li X., MacLellan W.R., Crooks G.M. Mapping the first stages of mesoderm commitment during differentiation of human embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:13742-13747.
112. Ardehali R., Ali S.R., Inlay M.A., Abilez O.J., Chen M.Q., Blauwkamp T.A., Yazawa M., Gong Y., Nusse R., Drukker M., Weissman I.L. Prospective isolation of human embryonic stem cell-derived cardiovascular progenitors that integrate into human fetal heart tissue. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:3405-3410.
113. Den Hartogh S.C., Schreurs C., Monshouwer-Kloots J.J., Davis R.P., Elliott D.A., Mummery C.L., Passier R. Dual reporter MESP1-NKX2-5 hESCs enable studying early human cardiac differentiation. Stem Cells 2015, 33(1):56-67.
114. Bu L., Jiang X., Martin-Puig S., Caron L., Zhu S., Shao Y., Roberts D.J., Huang P.L., Domian I.J., Chien K.R. Human ISL1 heart progenitors generate diverse multipotent cardiovascular cell lineages. Nature 2009, 460:113-117.
115. Ritner C., Wong S.S., King F.W., Mihardja S.S., Liszewski W., Erle D.J., Lee R.J., Bernstein H.S. An engineered cardiac reporter cell line identifies human embryonic stem cell-derived myocardial precursors. PLoS One 2011, 6:e16004.
116. Huber I., Itzhaki I., Caspi O., Arbel G., Tzukerman M., Gepstein A., Habib M., Yankelson L., Kehat I., Gepstein L. Identification and selection of cardiomyocytes during human embryonic stem cell differentiation. FASEB J. 2007, 21:2551-2563.
117. Ovchinnikov D.A., Hidalgo A., Yang S.K., Zhang X., Hudson J., Mazzone S.B., Chen C., Cooper-White J.J., Wolvetang E.J. Isolation of contractile cardiomyocytes from human pluripotent stem-cell-derived cardiomyogenic cultures using a human NCX1-EGFP reporter. Stem Cells Dev. 2015, 24(1):11-20.
118. Lock L.T., Tzanakakis E.S. Expansion and differentiation of human embryonic stem cells to endoderm progeny in a microcarrier stirred-suspension culture. Tissue Eng. A 2009, 15:2051-2063.
119. Vosough M., Omidinia E., Kadivar M., Shokrgozar M.A., Pournasr B., Aghdami N., Baharvand H. Generation of functional hepatocyte-like cells from human pluripotent stem cells in a scalable suspension culture. Stem Cells Dev. 2013, 22:2693-2705.
120. Niebruegge S., Bauwens C.L., Peerani R., Thavandiran N., Masse S., Sevaptisidis E., Nanthakumar K., Woodhouse K., Husain M., Kumacheva E., Zandstra P.W. Generation of human embryonic stem cell-derived mesoderm and cardiac cells using size-specified aggregates in an oxygen-controlled bioreactor. Biotechnol. Bioeng. 2009, 102:493-507.
121. Haraguchi Y., Matsuura K., Shimizu T., Yamato M., Okano T. Simple suspension culture system of human iPS cells maintaining their pluripotency for cardiac cell sheet engineering. J. Tissue Eng. Regen. Med. 2013, (Epub ahead of print). 10.1002/term.1761.
122. Lecina M., Ting S., Choo A., Reuveny S., Oh S. Scalable platform for human embryonic stem cell differentiation to cardiomyocytes in suspended microcarrier cultures. Tissue Eng. Part C Methods 2010, 16:1609-1619.
123. Ting S., Chen A., Reuveny S., Oh S. An intermittent rocking platform for integrated expansion and differentiation of human pluripotent stem cells to cardiomyocytes in suspended microcarrier cultures. Stem Cell Res. 2014, 13:202-213.
124. Kempf H., Kropp C., Olmer R., Martin U., Zweigerdt R. Cardiac differentiation of human pluripotent stem cells in scalable suspension culture. Nat. Protoc. 2015, 10:1345-1361.
125. Chong J.J., Yang X., Don C.W., Minami E., Liu Y.W., Weyers J.J., Mahoney W.M., Van Biber B., Cook S.M., Palpant N.J., Gantz J.A., Fugate J.A., Muskheli V., Gough G.M., Vogel K.W., Astley C.A., Hotchkiss C.E., Baldessari A., Pabon L., Reinecke H., Gill E.A., Nelson V., Kiem H.P., Laflamme M.A., Murry C.E. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 2014, 510:273-277.
126. Schroeder M., Niebruegge S., Werner A., Willbold E., Burg M., Ruediger M., Field L.J., Lehmann J., Zweigerdt R. Differentiation and lineage selection of mouse embryonic stem cells in a stirred bench scale bioreactor with automated process control. Biotechnol. Bioeng. 2005, 92:920-933.
127. Niebruegge S., Nehring A., Bar H., Schroeder M., Zweigerdt R., Lehmann J. Cardiomyocyte production in mass suspension culture: embryonic stem cells as a source for great amounts of functional cardiomyocytes. Tissue Eng. A 2008, 14:1591-1601.
128. Fridley K.M., Kinney M.A., McDevitt T.C. Hydrodynamic modulation of pluripotent stem cells. Stem Cell Res. Ther. 2012, 3:45.
129. Burridge P.W., Anderson D., Priddle H., Barbadillo Munoz M.D., Chamberlain S., Allegrucci C., Young L.E., Denning C. Improved human embryonic stem cell embryoid body homogeneity and cardiomyocyte differentiation from a novel V-96 plate aggregation system highlights interline variability. Stem Cells 2007, 25:929-938.
130. Mohr J.C., Zhang J., Azarin S.M., Soerens A.G., de Pablo J.J., Thomson J.A., Lyons G.E., Palecek S.P., Kamp T.J. The microwell control of embryoid body size in order to regulate cardiac differentiation of human embryonic stem cells. Biomaterials 2010, 31:1885-1893.
131. Dahlmann J., Kensah G., Kempf H., Skvorc D., Gawol A., Elliott D.A., Drager G., Zweigerdt R., Martin U., Gruh I. The use of agarose microwells for scalable embryoid body formation and cardiac differentiation of human and murine pluripotent stem cells. Biomaterials 2013, 34:2463-2471.
132. Hentze H., Soong P.L., Wang S.T., Phillips B.W., Putti T.C., Dunn N.R. Teratoma formation by human embryonic stem cells: evaluation of essential parameters for future safety studies. Stem Cell Res. 2009, 2:198-210.
133. Hattori F., Chen H., Yamashita H., Tohyama S., Satoh Y.S., Yuasa S., Li W., Yamakawa H., Tanaka T., Onitsuka T., Shimoji K., Ohno Y., Egashira T., Kaneda R., Murata M., Hidaka K., Morisaki T., Sasaki E., Suzuki T., Sano M., Makino S., Oikawa S., Fukuda K. Nongenetic method for purifying stem cell-derived cardiomyocytes. Nat. Methods 2010, 7:61-66.
134. Ban K., Wile B., Kim S., Park H.J., Byun J., Cho K.W., Saafir T., Song M.K., Yu S.P., Wagner M., Bao G., Yoon Y.S. Purification of cardiomyocytes from differentiating pluripotent stem cells using molecular beacons that target cardiomyocyte-specific mRNA. Circulation 2013, 128:1897-1909.
135. Miki K., Endo K., Takahashi S., Funakoshi S., Takei I., Katayama S., Toyoda T., Kotaka M., Takaki T., Umeda M., Okubo C., Nishikawa M., Oishi A., Narita M., Miyashita I., Asano K., Hayashi K., Osafune K., Yamanaka S., Saito H., Yoshida Y. Efficient detection and purification of cell populations using synthetic microRNA switches. Cell Stem Cell 2015, 16:699-711.
136. Tohyama S., Hattori F., Sano M., Hishiki T., Nagahata Y., Matsuura T., Hashimoto H., Suzuki T., Yamashita H., Satoh Y., Egashira T., Seki T., Muraoka N., Yamakawa H., Ohgino Y., Tanaka T., Yoichi M., Yuasa S., Murata M., Suematsu M., Fukuda K. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell 2013, 12:127-137.
137. Fuerstenau-Sharp M., Zimmermann M.E., Stark K., Jentsch N., Klingenstein M., Drzymalski M., Wagner S., Maier L.S., Hehr U., Baessler A., Fischer M., Hengstenberg C. Generation of highly purified human cardiomyocytes from peripheral blood mononuclear cell-derived induced pluripotent stem cells. PLoS One 2015, 10:e0126596.
138. Schwanke K., Merkert S., Kempf H., Hartung S., Jara-Avaca M., Templin C., Gohring G., Haverich A., Martin U., Zweigerdt R. Fast and efficient multitransgenic modification of human pluripotent stem cells. Hum. Gene Ther. Methods 2014, 25:136-153.
139. Merkert S., Wunderlich S., Bednarski C., Beier J., Haase A., Dreyer A.K., Schwanke K., Meyer J., Gohring G., Cathomen T., Martin U. Efficient designer nuclease-based homologous recombination enables direct PCR screening for footprintless targeted human pluripotent stem cells. Stem Cell Rep. 2014, 2:107-118.
140. Wang X., Wang Y., Wu X., Wang J., Wang Y., Qiu Z., Chang T., Huang H., Lin R.J., Yee J.K. Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. Nat. Biotechnol. 2015, 33:175-178.
141. Klug M.G., Soonpaa M.H., Koh G.Y., Field L.J. Genetically selected cardiomyocytes from differentiating embryonic stem cells form stable intracardiac grafts. J. Clin. Invest. 1996, 98:216-224.
142. Anderson D., Self T., Mellor I.R., Goh G., Hill S.J., Denning C. Transgenic enrichment of cardiomyocytes from human embryonic stem cells. Mol. Ther. 2007, 15:2027-2036.
143. Xu X.Q., Zweigerdt R., Soo S.Y., Ngoh Z.X., Tham S.C., Wang S.T., Graichen R., Davidson B., Colman A., Sun W. Highly enriched cardiomyocytes from human embryonic stem cells. Cytotherapy 2008, 10:376-389.
144. Kensah G., Roa Lara A., Dahlmann J., Zweigerdt R., Schwanke K., Hegermann J., Skvorc D., Gawol A., Azizian A., Wagner S., Maier L.S., Krause A., Drager G., Ochs M., Haverich A., Gruh I., Martin U. Murine and human pluripotent stem cell-derived cardiac bodies form contractile myocardial tissue in vitro. Eur. Heart J. 2013, 34(15):1134-1146.
145. He J.Q., Ma Y., Lee Y., Thomson J.A., Kamp T.J. Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circ. Res. 2003, 93:32-39.
146. Martin U. New muscle for old hearts: engineering tissue from pluripotent stem cells. Hum. Gene Ther. 2015, 26:305-311.
147. Xu X.Q., Soo S.Y., Sun W., Zweigerdt R. Global expression profile of highly enriched cardiomyocytes derived from human embryonic stem cells. Stem Cells 2009, 27:2163-2174.
148. Sartiani L., Bettiol E., Stillitano F., Mugelli A., Cerbai E., Jaconi M.E. Developmental changes in cardiomyocytes differentiated from human embryonic stem cells: a molecular and electrophysiological approach. Stem Cells 2007, 25:1136-1144.
149. Lundy S.D., Zhu W.Z., Regnier M., Laflamme M.A. Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells. Stem Cells Dev. 2013, 22:1991-2002.
150. Yang X., Rodriguez M., Pabon L., Fischer K.A., Reinecke H., Regnier M., Sniadecki N.J., Ruohola-Baker H., Murry C.E. Tri-iodo-l-thyronine promotes the maturation of human cardiomyocytes-derived from induced pluripotent stem cells. J. Mol. Cell. Cardiol. 2014, 72:296-304.
151. Feric N.T., Radisic M. Tri-iodo-l-thyronine promotes the maturation of human cardiomyocytes-derived from induced pluripotent stem cells. Adv. Drug Deliv. Rev 2016, 96:110-134.
152. Stoppel W.L., Kaplan D.L., Black Iii L.D. Electrical and mechanical stimulation of cardiac cells and tissue constructs. Adv. Drug Deliv. Rev 2016, 96:135-155.
153. Kraushaar U., Meyer T., Hess D., Gepstein L., Mummery C.L., Braam S.R., Guenther E. Cardiac safety pharmacology: from human ether-a-gogo related gene channel block towards induced pluripotent stem cell based disease models. Expert Opin. Drug Saf. 2012, 11:285-298.
154. Karakikes I., Ameen M., Termglinchan V., Wu J.C. Human induced pluripotent stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional phenotypes. Circ. Res. 2015, 117:80-88.
155. Lundy S.D., Murphy S.A., Dupras S.K., Dai J., Murry C.E., Laflamme M.A., Regnier M. Cell-based delivery of dATP via gap junctions enhances cardiac contractility. J. Mol. Cell. Cardiol. 2014, 72:350-359.
156. Sekine K., Kagawa Y., Maeyama E., Ota H., Haraguchi Y., Matsuura K., Shimizu T. Oxygen consumption of human heart cells in monolayer culture. Biochem. Biophys. Res. Commun. 2014, 452:834-839.
157. Mauritz C., Martens A., Rojas S.V., Schnick T., Rathert C., Schecker N., Menke S., Glage S., Zweigerdt R., Haverich A., Martin U., Kutschka I. Induced pluripotent stem cell (iPSC)-derived Flk-1 progenitor cells engraft, differentiate, and improve heart function in a mouse model of acute myocardial infarction. Eur. Heart J. 2011, 32:2634-2641.
158. Birket M.J., Ribeiro M.C., Verkerk A.O., Ward D., Leitoguinho A.R., den Hartogh S.C., Orlova V.V., Devalla H.D., Schwach V., Bellin M., Passier R., Mummery C.L. Expansion and patterning of cardiovascular progenitors derived from human pluripotent stem cells. Nat. Biotechnol. 2015, 33:970-979.